Omsättningen steg kraftigt efter att iZafe levererat 1000 enheter till Nederländerna.
Sales -2% vs. ABGSCe, -7% y-o-y Ework expects sales to decline H1'24 but to recover in H2'24 We expe...
Q1 var utmanande med svag efterfrågan och omsättningen minskade.
En historisk milstolpe har realiserats då AcuCort AB (”AcuCort” eller ”Bolaget”) har erhållit en för...
Cardeon AB (publ) (”Cardeon” eller ”Bolaget”) är ett investmentbolag som investerar i innovativa för...
Q1 2024 profit before loan losses came in at DKK 70m, DKK 4m (6%) ahead of our estimate.
Organic growth of 11% vs. cons. 10% Adj. EBITA SEK 128m, 13% below consensus Gross margin recovery i...
Redeye comments on Raketech’s preliminary Q1-results which are lower than expected as the company ha...
MTI Investment SE (”MTI” eller ”Bolaget”) meddelade den 30 april 2024 att Bolaget, genom dotterbolag...
Redeye comments on Freemelt’s new order from UKAEA, which deepens Freemelt’s position within the fus...
Q1: Clean EBIT of SEK 5m, production issues Pulp prices move higher, demand stronger Fair value rang...
Redeye endorses Optomed and AEYE Health’s FDA (510k) clearance of Aurora AEYE.
GC&MP outperforms, NW&FT takes a breather, FW lags behind Sales decline, but EBIT and cash flow bett...
Redeye reviews Medivir's fourth quarter report, which presented another improvement of median time t...
Redeye endorses that CLS’ partner, ClearPoint Neuro, has received FDA (510k) clearance for its Prism...
See what other investors are asking and the answers from Redeye's dedicated analyst in the latest An...
Sales SEK 458m -9% vs. ABGSCe 504m Adj. EBIT ~SEK -18m vs.
Loihde’s Q1 was a pleasant surprise, as we had expected a softer start to the year.
Redeye update on Embracer ahead of Q4-results (due 23 May) where we also adjust our estimates follow...
Kraftigt stigande bruttomarginal Nettoomsättningen ökade med 185% till 31,0 mkr (10,9).
